UBS Keeps Oscar Health at Neutral, Raises Price Target
UBS maintained its Neutral rating on Oscar Health while lifting the stock’s price target from $26 to $36 per share, Benzinga reported.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
UBS kept its Neutral rating on Oscar Health, according to Benzinga’s analyst-ratings section.
At the same time, the bank raised its price target for the stock to $36.00 per share from $26.00 previously.
why it matters
The unchanged rating alongside a higher target reflects an updated valuation assessment by UBS while preserving its neutral stance on Oscar Health shares.
instruments
sources
- Oscar Health Is Maintained at Neutral by UBS — Newsmetry API, 12 October 2026 at 21:22 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗